Previous Close | 6.68 |
Open | 6.67 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 6.43 - 6.69 |
52 Week Range | 3.28 - 8.87 |
Volume | |
Avg. Volume | 1,945,572 |
Market Cap | 405.048M |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.22 |
Earnings Date | Feb 20, 2023 - Feb 24, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.36 |
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s N
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.